Neurology

#ALS #Autism #Neurology #Neuroscience #Schizophrenia

This week in drug discovery (1-5 April) 

News round-up for 1-5 April by DDW Digital Content Editor Diana Spencer. This has been a busy week in the field of neuroscience drug discovery, with EU approval for a long-acting schizophrenia treatment, research revealing new insights into autism, the formation of a partnership focused on ALS drug… Read More

#News

#Financing #Neurology #Neurosterix #Schizophrenia #Start-ups

$63m for allosteric modulators for neurological disorders

Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. The company will acquire Addex’s allosteric modulator discovery technology platform. The platform has a track record of identifying highly… Read More

#Editor's Choice #News #Start-up Zone

#Biologics / Biotechnology #Cell therapy #CNS #Financing #Kenai Therapeutics #Neurology #Parkinson's

$82m investment in cell therapies for neurological diseases

Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors… Read More

#Business & Investment #News

A scientist examines brain scans on a large screen
#CNS #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife

The era of precision neuroscience

Listen to this article on the DDW Podcast: Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Human disease models #Interview #Neurology #Neuroscience #Stem cells

Putting human data at the centre of drug discovery

Listen to this article on the DDW Podcast: James Peach is the Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. Peach shared his insight with DDW’s Megan Thomas. MT: In what ways can human… Read More

#Exclusive Content #Opinion

Neuron
#ALS #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells #Whitepaper

Whitepaper: Explore iPSC-derived motor neuron morphology

A new whitepaper is now available from DDW and Sartorius entitled ‘iPSC-Derived Motor Neurons and Microglia From ALS Background Display Disease Phenotype’. Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients… Read More

#News

#ALS #Drug discovery #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells

Using patient-specific cells for disease modelling

Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients and have the potential to guide these cells towards multiple lineages. Download the whitepaper to: Explore iPSC-derived motor neuron morphology Discover how ALS disease phenotype… Read More

#Resources

Neurons
#Anxiety disorder #Neurology #Neuroscience #Tokyo University of Science

Scientists identify potential new therapeutic target for anxiety

A new study has highlighted the role of specific neuronal circuits in the brain involved in the development of anxiety, and distinct mechanisms of action of the therapeutic delta opioid receptor (DOP) agonist KNT-127. Understanding the neural circuits and molecular mechanisms that trigger anxiety can aid… Read More

#News

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

Neuroscience innovation
#AI #Alzheimer's #Artificial intelligence (AI) #Biomarkers #Brain disease #Drug discovery #Inherited tauopathies #Mental health #Nervous system disorders #Neurodegenerative disorders #Neurology #Neuroscience #Neurotechnology #Psychiatry #Tau protein

New podcast on innovation in neuroscience

This is the latest episode of the free DDW narrated podcast, titled “Where is the latest innovation in neuroscience?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Taking a new approach to tackle neurodegenerative diseases,… Read More

#News

#Drug discovery #iPSC #Neurology #Preclinical development #Preclinical investigations

Case Study: How to generate publishable data in just 12 weeks

A new resource is now available to download for free from sponsors Bit Bio: ‘Speeding up neuroscience research: Generating publishable data in 12 weeks‘. In this Case Study you will learn: How Professor Deepak Srivastava’s lab at King’s College London are working to unpick the complex… Read More

#News

#Drug discovery #iPSC #Neurology #Preclinical development #Preclinical investigations

Speeding up neuroscience research: Generating publishable data in 12 weeks

In this Case Study you will learn: How Professor Deepak Srivastava’s lab at King’s College London are working to unpick the complex biology of neuronal synapses to help us better understand neurological disorders like schizophrenia. How the researchers in Professor Srivastava’s lab have been able to generate publishable data… Read More

#Resources

Immunity
#Immunity #Neurology #Novartis #Sitting Down With

Sitting down with… Catherine Emond, Novartis  

Catherine Emond is the Head of Immunology and Neuroscience at Novartis UK. She is responsible for driving long-term strategies that can help change the lives of people with challenging immunological and neurological conditions. With over two decades of leadership experience, Emond is known for her broad brand lifecycle management achievements… Read More

#Exclusive Content

#Alzheimer's #Drug discovery #Neurology #Stem cells

bit.bio launches stem cell line for neuro research and screening  

Biotechnology company bit.bio has launched a range of immune cells to provide researchers with a consistently functional and rapid human in vitro model for the study of neuroinflammation and neurodegenerative diseases.  The company’s ioMicroglia cell range is designed to recapitulate key human microglia functions and… Read More

#News

#Biotechnology #Concussion #Neurology #Neuroscience #Oxeia Biopharmaceuticals #University of Kansas Medical Center (KUMC)

“Game changing” concussion drug study shows positive early results  

Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC).   The study results suggest a potentially… Read More

#News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovative advances in neuroscience: Secure your place

It’s less than one week now till our exclusive online event ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. Register now to secure your place on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You… Read More

Webinar date:
#News